Trials / Active Not Recruiting
Active Not RecruitingNCT04755283
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,287 (actual)
- Sponsor
- Anthos Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Abelacimab | Abelacimab provided as liquid in vial (150 mg/mL) |
| DRUG | Rivaroxaban | Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets |
Timeline
- Start date
- 2021-02-02
- Primary completion
- 2024-02-15
- Completion
- 2028-12-29
- First posted
- 2021-02-16
- Last updated
- 2025-11-06
- Results posted
- 2025-07-30
Locations
92 sites across 7 countries: United States, Canada, Czechia, Hungary, Poland, South Korea, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04755283. Inclusion in this directory is not an endorsement.